{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:35:13Z","timestamp":1754109313288},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.7759\/cureus.70125","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:19:41Z","timestamp":1727223581000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety and Efficacy of Upadacitinib in Crohn\u2019s Disease: An Updated Systematic Review"],"prefix":"10.7759","author":[{"given":"Aliu O","family":"Olatunji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ali","family":"Abid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik Sai","family":"Makineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Khaleel I.KH.","family":"Almadhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamdah B","family":"Meer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazeela","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma M","family":"Alfakhori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adees W","family":"Bedros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasreen","family":"Banu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Faqeer Hussain","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15592585","article-title":"Crohn's disease: a clinical update","volume":"8","author":"Ha F","year":"2015","unstructured":"Ha F, Khalil H. Crohn's disease: a clinical update. Therap Adv Gastroenterol. 2015, 8:352-9. 10.1177\/1756283X15592585","journal-title":"Therap Adv Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-17431-8","article-title":"Trends and projections of inflammatory bowel disease at the global, regional and national levels, 1990-2050: a bayesian age-period-cohort modeling study","volume":"23","author":"Zhou JL","year":"2023","unstructured":"Zhou JL, Bao JC, Liao XY, et al.. Trends and projections of inflammatory bowel disease at the global, regional and national levels, 1990-2050: a bayesian age-period-cohort modeling study. BMC Public Health. 2023, 23:2507. 10.1186\/s12889-023-17431-8","journal-title":"BMC Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S360248","article-title":"Personalized treatment for Crohn\u2019s disease: current approaches and future directions","volume":"16","author":"Clinton JW","year":"2023","unstructured":"Clinton JW, Cross RK. Personalized treatment for Crohn\u2019s disease: current approaches and future directions. Clin Exp Gastroenterol. 2023, 16:249-76. 10.2147\/CEG.S360248","journal-title":"Clin Exp Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams DM","year":"2018","unstructured":"Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018, 63:655-70. 10.4187\/respcare.06314","journal-title":"Respir Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.19087","article-title":"Immunomodulatory drugs: oral and systemic adverse effects","volume":"19","author":"Bascones-Martinez A","year":"2014","unstructured":"Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman JH. Immunomodulatory drugs: oral and systemic adverse effects. Med Oral Patol Oral Cir Bucal. 2014, 19:e24-31. 10.4317\/medoral.19087","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05136-x","article-title":"The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era","volume":"42","author":"Evangelatos G","year":"2022","unstructured":"Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int. 2022, 42:1493-511. 10.1007\/s00296-022-05136-x","journal-title":"Rheumatol Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50657","article-title":"Upadacitinib in Crohn's disease: a comprehensive systematic review of efficacy and safety","volume":"15","author":"Wodeyar AM","year":"2023","unstructured":"Wodeyar AM, Pansuriya N, Saeed S, et al.. Upadacitinib in Crohn's disease: a comprehensive systematic review of efficacy and safety. Cureus. 2023, 15:e50657. 10.7759\/cureus.50657","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8227","article-title":"Symptomatic creatine phosphokinase elevation in a Crohn's disease patient caused by upadacitinib","volume":"12","author":"Schuitema A","year":"2024","unstructured":"Schuitema A, Anjie SI, van Eeghen AM, Tas SW, L\u00f6wenberg M. Symptomatic creatine phosphokinase elevation in a Crohn's disease patient caused by upadacitinib. Clin Case Rep. 2024, 12:e8227. 10.1002\/ccr3.8227","journal-title":"Clin Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1513","article-title":"Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib","volume":"60","author":"Mohamed MF","year":"2020","unstructured":"Mohamed MF, Beck D, Camp HS, Othman AA. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol. 2020, 60:188-97. 10.1002\/jcph.1513","journal-title":"J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes IB","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, et al.. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019, 21:183. 10.1186\/s13075-019-1964-1","journal-title":"Arthritis Res Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051734","article-title":"Upadacitinib for patients with rheumatoid arthritis: a comprehensive review","volume":"12","author":"Sanmart\u00ed R","year":"2023","unstructured":"Sanmart\u00ed R, Corominas H. Upadacitinib for patients with rheumatoid arthritis: a comprehensive review. J Clin Med. 2023, 12:1734. 10.3390\/jcm12051734","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S367086","article-title":"Clinical evaluation of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis (UC): patient selection and reported outcomes","volume":"16","author":"Irani M","year":"2023","unstructured":"Irani M, Fan C, Glassner K, Abraham BP. Clinical evaluation of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis (UC): patient selection and reported outcomes. Clin Exp Gastroenterol. 2023, 16:21-8. 10.2147\/CEG.S367086","journal-title":"Clin Exp Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012corr1","article-title":"Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"9","year":"2023","unstructured":"Correction. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2023, 9:10.1136\/rmdopen-2021-002012corr1","journal-title":"RMD Open"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2023.0142","article-title":"Treatment strategies in inflammatory bowel diseases","volume":"120","author":"Stallmach A","year":"2023","unstructured":"Stallmach A, Atreya R, Grunert PC, Stallhofer J, de Laffolie J, Schmidt C. Treatment strategies in inflammatory bowel diseases. Dtsch Arztebl Int. 2023, 120:768-78. 10.3238\/arztebl.m2023.0142","journal-title":"Dtsch Arztebl Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.02.027","article-title":"Upadacitinib reduces Crohn's disease symptoms within the first week of induction therapy","volume":"22","author":"Colombel JF","year":"2024","unstructured":"Colombel JF, Hisamatsu T, Atreya R, et al.. Upadacitinib reduces Crohn's disease symptoms within the first week of induction therapy. Clin Gastroenterol Hepatol. 2024, 22:1668-77. 10.1016\/j.cgh.2024.02.027","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.02.026","article-title":"Upadacitinib achieves clinical and endoscopic outcomes in Crohn's disease regardless of prior biologic exposure","author":"Peyrin-Biroulet L","year":"2024","unstructured":"Peyrin-Biroulet L, Panaccione R, Louis E, et al.. Upadacitinib achieves clinical and endoscopic outcomes in Crohn's disease regardless of prior biologic exposure. Clin Gastroenterol Hepatol. 2024, 10.1016\/j.cgh.2024.02.026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus EV Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, et al.. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med. 2023, 388:1966-80. 10.1056\/NEJMoa2212728","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study","volume":"15","author":"Elford AT","year":"2024","unstructured":"Elford AT, Bishara M, Plevris N, et al.. Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study. Frontline Gastroenterol. 2024, 15:297-304. 10.1136\/flgastro-2024-102668","journal-title":"Frontline Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn's disease: prospective real-world experience","volume":"21","author":"Friedberg S","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T, et al.. Upadacitinib is effective and safe in both ulcerative colitis and Crohn's disease: prospective real-world experience. Clin Gastroenterol Hepatol. 2023, 21:1913-1923.e2. 10.1016\/j.cgh.2023.03.001","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.030","article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn's disease in the CELEST extension study","volume":"20","author":"D'Haens G","year":"2022","unstructured":"D'Haens G, Pan\u00e9s J, Louis E, Lacerda A, Zhou Q, Liu J, Loftus EV Jr. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn's disease in the CELEST extension study. Clin Gastroenterol Hepatol. 2022, 20:2337-2346.e3. 10.1016\/j.cgh.2021.12.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr, et al.. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. Gastroenterology. 2020, 158:2123-2138.e8. 10.1053\/j.gastro.2020.01.047","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002947","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in ulcerative colitis: a US propensity-matched cohort study","author":"Kochhar GS","year":"2024","unstructured":"Kochhar GS, Khataniar H, Jairath V, Farraye FA, Desai A. Comparative effectiveness of upadacitinib and tofacitinib in ulcerative colitis: a US propensity-matched cohort study. Am J Gastroenterol. 2024, 10.14309\/ajg.0000000000002947","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297361-safety-and-efficacy-of-upadacitinib-in-crohns-disease-an-updated-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:19:43Z","timestamp":1727223583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297361-safety-and-efficacy-of-upadacitinib-in-crohns-disease-an-updated-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.70125","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}